Why the study?
Does in-treatment measurement of subclinical organ damage improve prediction of cardiovascular events compared to in-treatment Framingham risk score in hypertensive patients?
Does in-treatment measurement of subclinical organ damage improve prediction of cardiovascular events compared to in-treatment Framingham risk score in hypertensive patients?
Answers are grounded in this paper and cite their sources.
In-treatment changes in subclinical organ damage (ECG LVH and UACR) are better predictors of subsequent cardiovascular risk than changes in the Framingham risk score during antihypertensive therapy.
AIM: To investigate whether in-treatment measurements of subclinical organ damage (SOD) assessed by elevated urine albumin/creatinine ratio (UACR) or electrocardiographic left ventricular hypertrophy improved the prediction of the composite cardiovascular endpoint of cardiovascular death, nonfatal myocardial infarction and stroke beyond in-treatment Framingham risk score (FRS). METHODS: Excluding patients with a composite cardiovascular endpoint within the first year of treatment, 598 endpoints occurred in 6460 patients from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study with baseline and 1 year values for UACR, left ventricular hypertrophy by electrocardiography and FRS available. RESULTS: Using Cox-regression analyses, FRS(1year) [hazard ratio=1.006 (0.98-1.04)] did not predict the endpoint independently of history of cardiovascular disease [hazard ratio=1.76 (1.49-2.08)], FRS(baseline) [hazard ratio=1.07 (1.04-1.11)], UACR(baseline) [hazard ratio=1.15 (1.07-1.23), all three P<0.001], Sokolow-Lyon(baseline) [hazard ratio=1.01 (1.006-1.02), P<0.01] and treatment allocation, whereas Cornell product(1year) [hazard ratio=1.01 (1.006-1.02), P<0.001] and to some degree UACR(1year) [hazard ratio=1.05 (0.99-1.10), P=0.09] predicted the endpoint independently of history of cardiovascular disease [hazard ratio=1.71 (1.44-2.02)], FRS(baseline) [hazard ratio=1.08 (1.06-1.10)], Sokolow-Lyon(baseline) [hazard ratio=1.01 (1.007-1.02), both P<0.001], UACR(baseline) [hazard ratio=1.11 (1.03-1.20), P<0.01] and treatment allocation decreasing -2 Log likelihood significantly (P<0.01).Presence of left ventricular hypertrophy by Cornell product(1year) or UACR(1year) at least 1 mmol/l [hazard ratio=1.40 (1.15-1.70), P=0.001] but not FRS(1year) above the median baseline value of 20 [hazard ratio=1.22 (0.94-1.57), not significant] was associated with higher risk of subsequent endpoint after adjustment for history of cardiovascular disease [hazard ratio=1.82 (1.54-2.15)], FRS(baseline) at least 20 [hazard ratio=1.67 (1.30-2.16)], left ventricular hypertrophy by Sokolow-Lyon(baseline) or UACR(baseline) at least 1 mmol/l [hazard ratio=1.61 (1.33-1.94), all P<0.001] and treatment allocation [hazard ratio=0.93 (0.79-1.09), not significant]. In contrast to FRS(1year) at least 20 decreased, SOD(1year) decreased -2Log likelihood significantly (P<0.01). CONCLUSION: Cornell product(1year) and UACR(1year) improved in contrast to FRS(1year) risk prediction based on FRS(baseline), Sokolow-Lyon(baseline) and UACR(baseline) significantly in LIFE patients during antihypertensive treatment.
No takes yet. Share an insight, caveat, or question.
Olsen et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: